Robertson et al [26] |
Intermittent ML vs. placebo |
220 |
Intermittent ML superior to placebo |
Bacharier et al [27] |
Intermittent ML vs. intermittent nebulised
BUD vs. placebo |
238 |
Intermittent ML and nebulized BUD equivalent and
better than placebo |
Valovirta et al [28] |
Intermittent ML vs. continuous ML vs. placebo |
1771 |
No benefit of either ML regime |
Nwokoro et al [29]
|
Intermittent ML vs. placebo
Sub analysis by ALOX5 promoter polymorphisms
|
1346
|
No benefit of ML
Possible benefit of ALOX5 promoter genotyping
|